Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
GENEVA, SWITZERLAND / ACCESSWIRE / October 26, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), today announced that they and NRx Pharmaceuticals, Inc. ("NRx") have agreed to extend the stay of their pending litigation until November 7, 2022 to allow time...
Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission to Reverse Split and Change the Ratio of its ADRs to Ordinary Shares from 1 to 150 to 1 to 200 GENEVA, SWITZERLAND / ACCESSWIRE / October 25, 2022 / RELIEF T...
Relief Therapeutics ( OTCQB:RLFTF ) has announced that Paolo Galfetti has been promoted to Chief Operating Officer, effective October 14, 2022. Paolo will continue his responsibilities as CEO of APR Applied Pharma Research and as a member of Relief's Board of Directors. ...
GENEVA, SWITZERLAND / ACCESSWIRE / October 14, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare an...
Relief Therapeutics ( OTCQB:RLFTF )( OTCQB:RLFTY ) said it launched medical food product PKU GOLIKE in the U.S. for the dietary management of phenylketonuria (PKU) PKU is a rare inherited disorder caused by a defect in an enzyme needed to break down an amino acid ...
First sale of PKU Golike ® in the U.S. through Relief's exclusive national distributor Relief will issue milestone payment and increase its share capital to create 200 million additional treasury shares GENEVA, SWITZERLAND / ACCESSWIRE / October 10, 2022 / RELIEF THERAPEUTICS...
Relief Therapeutics ( OTCQB:RLFTF ) has hired a leading provider of food for special medical purposes to help maximize patient access in support of PKU GOLIKE ® U.S. launch. PKU GOLIKE ® is a next generation medical food product engineered with the paten...
Leading Provider of Food for Special Medical Purposes to Help Maximize Patient Access in Support of PKU GOLIKE ® U.S. Launch GENEVA, SWITZERLAND / ACCESSWIRE / October 6, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a Swiss, commercial-sta...
NEWTON, Mass. and GENEVA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief) today announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance to Acer for U...
Relief Therapeutics ( OTCQB:RLFTF ) ( OTCQB:RLFTY ) said that an investigator initiated trial of Nexodyn for a rare skin disorders called Epidermolysis Bullosa (EB) received IRB approval and will shortly begin enrolling participants. The Swiss company noted that the...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
Mondobiotech Holding AG Basel Website:
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, ann...
GENEVA, SWITZARLAND / ACCESSWIRE / May 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Mee...
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the formation of its ne...